Identification

Name
Nabumetone
Accession Number
DB00461  (APRD01128)
Type
Small Molecule
Groups
Approved
Description

Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid family (which includes diclofenac). Marketed under the brand name Relafen, it has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs.

Structure
Thumb
Synonyms
  • 4-(6-Methoxy-2-naphthalenyl)-2-butanone
  • 4-(6-Methoxy-2-naphthyl)-2-butanone
  • Nabumeton
  • Nabumetona
  • Nabumétone
  • Nabumetone
  • Nabumetonum
External IDs
BRL 14777
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NabumetoneTablet500 mgOralAa Pharma Inc1998-08-21Not applicableCanada
NabumetoneTablet500 mgOralSanis Health Inc2010-02-162017-02-08Canada
Nabumetone-500Tablet500 mgOralPro Doc Limitee2008-04-072010-07-13Canada
Relafen Tablets 500mgTablet500 mgOralGlaxosmithkline Inc1994-12-312006-02-13Canada
Relafen Tablets 750mgTablet750 mgOralGlaxosmithkline Inc1998-01-292006-02-13Canada
Sandoz NabumetoneTablet500 mgOralSandoz Canada Incorporated2002-02-212008-08-07Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mylan-nabumetoneTablet500 mgOralMylan Pharmaceuticals2002-02-202017-01-09Canada
NabumetoneTablet, film coated750 mg/1OralAv Kare, Inc.2014-01-202017-11-04Us
NabumetoneTablet500 mg/1OralBlenheim Pharmacal, Inc.2010-03-24Not applicableUs
NabumetoneTablet500 mg/1OralMajor2009-06-10Not applicableUs
NabumetoneTablet, film coated500 mg/1OralCardinal Health2010-08-062018-02-23Us
NabumetoneTablet, film coated500 mg/1OralSt.mary's Medical Park Pharmacy2008-03-01Not applicableUs
NabumetoneTablet, film coated500 mg/1OralAv Pak2016-11-22Not applicableUs
NabumetoneTablet, film coated750 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2008-03-01Not applicableUs
NabumetoneTablet, film coated750 mg/1OralLiberty Pharmaceuticals, Inc.2015-04-14Not applicableUs
NabumetoneTablet, film coated750 mg/1OralA S Medication Solutions2008-03-012016-10-19Us
International/Other Brands
Arthaxan (SmithKline Beecham (Germany; discontinued)) / Balmox (Beecham (Portugal), Meda (Switzerland)) / Dolsinal (Ferrer (Spain; discontinued)) / Listran (Uriach (Spain)) / Mebutan (Meda (Netherlands)) / Nabuser (Geymonat (Italy)) / Relafen (GlaxoSmithKline (Canada, USA; discontinued)) / Relif (Meda (Spain)) / Relifen (Sanwa (Japan), GSK (South Africa)) / Relifex (Meda (Czeck Republic, Denmark, Finland, Germany, Greece, Hungary, Ireland, Italy, Norway, Sweden, United Kingdom), GSK (Israel, Mexico, Poland, Thailand, Turkey), SmithKline Beecham (Philippines))
Categories
UNII
LW0TIW155Z
CAS number
42924-53-8
Weight
Average: 228.2863
Monoisotopic: 228.115029756
Chemical Formula
C15H16O2
InChI Key
BLXXJMDCKKHMKV-UHFFFAOYSA-N
InChI
InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
IUPAC Name
4-(6-methoxynaphthalen-2-yl)butan-2-one
SMILES
COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2

Pharmacology

Indication

For acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.

Structured Indications
Pharmacodynamics

Nabumetone is a naphthylalkanone. Is is a non-selective prostaglandin G/H synthase (a.k.a. cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to prostaglandin G2 and prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is the precursor to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. The parent compound is a prodrug that undergoes hepatic biotransformation to the active compound, 6-methoxy-2-naphthylacetic acid (6MNA). The analgesic, antipyretic and anti-inflammatory effects of NSAIDs occur as a result of decreased prostaglandin synthesis.

Mechanism of action

The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis, most likely through binding to the COX-2 and COX-1 receptors.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Well absorbed from the gastrointestinal tract. Coadministration of food increases the rate of absorption and subsequent appearance of 6MNA (the active metabolite) in the plasma but does not affect the extent of conversion of nabumetone into 6MNA.

Volume of distribution
Not Available
Protein binding

The active metabolite, 6MNA, is more than 99% bound to plasma proteins.

Metabolism

Undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine.

Route of elimination

Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine.

Half life

Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency.

Clearance
  • 20 - 30 mL/min
Toxicity

The one overdose occurred in a 17-year-old female patient who had a history of abdominal pain and was hospitalized for increased abdominal pain following ingestion of 30 nabumetone tablets (15 grams total). Stools were negative for occult blood and there was no fall in serum hemoglobin concentration. The patient had no other symptoms.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nabumetone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Nabumetone.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 5-androstenedione.Experimental, Illicit
AbciximabNabumetone may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Nabumetone can be increased when it is combined with Abiraterone.Approved
AcebutololNabumetone may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Nabumetone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Nabumetone is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolNabumetone may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nabumetone.Approved, Vet Approved
AclarubicinNabumetone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Nabumetone.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Nabumetone.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Nabumetone.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Aldosterone.Experimental, Investigational
AldoxorubicinNabumetone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.Approved
AliskirenNabumetone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Nabumetone.Experimental
AlprenololNabumetone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nabumetone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Amcinonide.Approved
AmikacinNabumetone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideNabumetone may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinNabumetone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodNabumetone may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Nabumetone.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Nabumetone is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Nabumetone is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Nabumetone.Investigational
AnnamycinNabumetone may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nabumetone.Approved, Investigational
Antithrombin III humanNabumetone may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanNabumetone may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Nabumetone.Investigational
ApramycinNabumetone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Nabumetone.Approved, Investigational
ArbekacinNabumetone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinNabumetone may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNabumetone may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNabumetone may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Atamestane.Investigational
AtenololNabumetone may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Nabumetone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nabumetone.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Nabumetone is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabumetone.Approved, Investigational
AzithromycinThe metabolism of Nabumetone can be decreased when combined with Azithromycin.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nabumetone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nabumetone.Approved, Investigational
BecaplerminNabumetone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNabumetone may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinNabumetone may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Nabumetone.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nabumetone.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Nabumetone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nabumetone.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Nabumetone.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nabumetone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Betamethasone.Approved, Vet Approved
BetaxololNabumetone may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Nabumetone.Approved, Investigational
BevantololNabumetone may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Nabumetone.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nabumetone.Approved, Investigational
BisoprololNabumetone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNabumetone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNabumetone may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Nabumetone can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nabumetone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Nabumetone.Investigational
BucindololNabumetone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Nabumetone.Approved, Experimental
BufuralolNabumetone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Nabumetone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nabumetone.Approved
BupranololNabumetone may decrease the antihypertensive activities of Bupranolol.Approved
CaffeineThe metabolism of Nabumetone can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nabumetone.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nabumetone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Nabumetone.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nabumetone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Nabumetone.Approved, Vet Approved, Withdrawn
CarteololNabumetone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNabumetone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nabumetone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Celecoxib.Approved, Investigational
CeliprololNabumetone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNabumetone may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nabumetone.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nabumetone.Approved, Vet Approved
ChlorotrianiseneNabumetone may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nabumetone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nabumetone.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Cilazapril.Approved
CinoxacinNabumetone may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the antiplatelet activities of Nabumetone.Approved
Citric AcidNabumetone may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Nabumetone.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nabumetone.Vet Approved
CloranololNabumetone may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneNabumetone may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Nabumetone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensNabumetone may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Nabumetone.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nabumetone.Experimental
CyclosporineNabumetone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Nabumetone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateNabumetone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinNabumetone may increase the thrombogenic activities of Daidzein.Experimental
DalteparinNabumetone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNabumetone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Nabumetone.Investigational
DarexabanNabumetone may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinNabumetone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Delapril.Experimental
DesirudinNabumetone may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Nabumetone.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nabumetone.Approved, Investigational
DextranNabumetone may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinNabumetone may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Nabumetone is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nabumetone.Approved, Vet Approved
DicoumarolNabumetone may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolNabumetone may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolNabumetone may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Nabumetone.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nabumetone.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nabumetone.Approved
DihydrostreptomycinNabumetone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nabumetone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nabumetone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nabumetone.Approved
DiphenadioneNabumetone may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe metabolism of Nabumetone can be decreased when combined with Dosulepin.Approved
DoxorubicinNabumetone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNabumetone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Nabumetone.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Nabumetone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Nabumetone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Nabumetone.Investigational
Edetic AcidNabumetone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNabumetone may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Nabumetone is combined with Enalaprilat.Approved
EnoxacinNabumetone may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinNabumetone may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Nabumetone.Experimental
EpanololNabumetone may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolNabumetone may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Nabumetone.Approved
EpirubicinNabumetone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nabumetone.Experimental
EplerenoneNabumetone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nabumetone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nabumetone.Approved
EquileninThe risk or severity of adverse effects can be increased when Nabumetone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Nabumetone is combined with Equilin.Approved
EquolNabumetone may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Nabumetone.Approved, Investigational
EsmololNabumetone may decrease the antihypertensive activities of Esmolol.Approved
EstradiolNabumetone may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateNabumetone may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateNabumetone may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateNabumetone may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolNabumetone may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedNabumetone may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneNabumetone may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nabumetone.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Nabumetone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Nabumetone.Experimental
Ethinyl EstradiolNabumetone may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateNabumetone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Nabumetone.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Nabumetone.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Nabumetone.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Nabumetone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Nabumetone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Nabumetone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nabumetone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nabumetone.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Nabumetone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Nabumetone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Nabumetone.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nabumetone.Approved, Investigational
FleroxacinNabumetone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nabumetone.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fludrocortisone.Approved, Investigational
FluindioneNabumetone may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineNabumetone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Nabumetone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Nabumetone.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nabumetone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Nabumetone.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nabumetone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nabumetone.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Nabumetone can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nabumetone.Approved, Nutraceutical, Vet Approved
FondaparinuxNabumetone may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumNabumetone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nabumetone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fosinopril.Approved
FramycetinNabumetone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nabumetone.Approved, Vet Approved
GabexateNabumetone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNabumetone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNabumetone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nabumetone.Approved, Withdrawn
GemifloxacinNabumetone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNabumetone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinNabumetone may increase the thrombogenic activities of Genistein.Investigational
GentamicinNabumetone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANabumetone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Nabumetone may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinNabumetone may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Nabumetone.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Nabumetone is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Nabumetone is combined with HE3286.Investigational
HeparinNabumetone may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolNabumetone may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Nabumetone.Investigational
HydralazineNabumetone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nabumetone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nabumetone.Approved, Investigational
Hygromycin BNabumetone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nabumetone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Nabumetone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Nabumetone.Approved, Investigational
IdarubicinNabumetone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxNabumetone may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nabumetone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Nabumetone.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Nabumetone.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nabumetone.Approved
IndenololNabumetone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Nabumetone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nabumetone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Nabumetone.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nabumetone.Approved, Investigational
IsepamicinNabumetone may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Nabumetone.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Nabumetone is combined with Istaroxime.Investigational
KanamycinNabumetone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Nabumetone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nabumetone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nabumetone.Approved
LabetalolNabumetone may decrease the antihypertensive activities of Labetalol.Approved
LandiololNabumetone may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nabumetone.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Nabumetone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Nabumetone.Approved, Investigational
LepirudinNabumetone may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanNabumetone may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololNabumetone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNabumetone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Nabumetone.Approved, Investigational
LidocaineThe metabolism of Nabumetone can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Nabumetone.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nabumetone.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Nabumetone.Approved
LobeglitazoneThe metabolism of Nabumetone can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Nabumetone.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Nabumetone.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nabumetone.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Nabumetone.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nabumetone.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Nabumetone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nabumetone.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nabumetone.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Nabumetone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nabumetone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nabumetone.Approved
MelagatranNabumetone may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nabumetone.Approved, Vet Approved
MepindololNabumetone may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nabumetone.Approved
MestranolNabumetone may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Nabumetone.Approved, Investigational, Withdrawn
MethallenestrilNabumetone may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nabumetone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNabumetone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone.Approved
MetoprololNabumetone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNabumetone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Nabumetone can be decreased when combined with Mexiletine.Approved, Investigational
MicronomicinNabumetone may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Nabumetone can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Nabumetone.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Nabumetone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nabumetone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Nabumetone.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Nabumetone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nabumetone.Approved
MoxestrolNabumetone may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nabumetone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nabumetone.Approved
NadololNabumetone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNabumetone may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Nabumetone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nabumetone.Approved
Nalidixic AcidNabumetone may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Nabumetone.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Nabumetone is combined with NCX 1022.Investigational
NeamineNabumetone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololNabumetone may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Nabumetone.Approved, Withdrawn
NemonoxacinNabumetone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNabumetone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nabumetone.Approved, Investigational
NetilmicinNabumetone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NevirapineThe metabolism of Nabumetone can be decreased when combined with Nevirapine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Nabumetone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nabumetone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nabumetone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Nabumetone.Investigational
NorfloxacinNabumetone may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nabumetone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nabumetone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nabumetone.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Nabumetone is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Nabumetone is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Nabumetone.Vet Approved
OsimertinibThe serum concentration of Nabumetone can be decreased when it is combined with Osimertinib.Approved
OtamixabanNabumetone may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nabumetone.Approved
Oxolinic acidNabumetone may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNabumetone may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nabumetone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Parecoxib.Approved
ParomomycinNabumetone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Nabumetone.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Nabumetone.Approved, Investigational
PazufloxacinNabumetone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNabumetone may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololNabumetone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateNabumetone may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateNabumetone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Perindopril.Approved
PhenindioneNabumetone may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonNabumetone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nabumetone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nabumetone.Approved, Investigational
PindololNabumetone may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidNabumetone may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinNabumetone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nabumetone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nabumetone.Approved, Investigational
Piromidic acidNabumetone may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nabumetone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Nabumetone.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorNabumetone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinNabumetone may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinNabumetone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Polyestradiol phosphateNabumetone may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nabumetone.Approved
PractololNabumetone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nabumetone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Nabumetone.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Nabumetone can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Nabumetone.Experimental
PromestrieneNabumetone may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Nabumetone.Approved, Investigational
PropranololNabumetone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Nabumetone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Nabumetone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nabumetone.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nabumetone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Nabumetone.Vet Approved
Protein CNabumetone may increase the anticoagulant activities of Protein C.Approved
Protein S humanNabumetone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNabumetone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNabumetone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Nabumetone.Investigational
PuromycinNabumetone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Quinapril.Approved, Investigational
QuinestrolNabumetone may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nabumetone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Nabumetone is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nabumetone.Approved, Experimental, Investigational
ReviparinNabumetone may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinNabumetone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Risedronate.Approved, Investigational
RivaroxabanNabumetone may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Rofecoxib.Approved, Investigational, Withdrawn
RopiniroleThe metabolism of Nabumetone can be decreased when combined with Ropinirole.Approved, Investigational
RosoxacinNabumetone may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Nabumetone can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinNabumetone may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinNabumetone may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nabumetone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Nabumetone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nabumetone.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Nabumetone.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nabumetone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nabumetone.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Nabumetone.Approved, Investigational
SecoisolariciresinolNabumetone may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Nabumetone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nabumetone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Nabumetone.Investigational
SertralineSertraline may increase the antiplatelet activities of Nabumetone.Approved
SimeprevirThe metabolism of Nabumetone can be decreased when combined with Simeprevir.Approved
SisomicinNabumetone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinNabumetone may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Nabumetone.Approved
SotalolNabumetone may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNabumetone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNabumetone may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinNabumetone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Spirapril.Approved
SpironolactoneNabumetone may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Nabumetone.Investigational
StreptomycinNabumetone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNabumetone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nabumetone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nabumetone.Approved, Investigational
SulodexideNabumetone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nabumetone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Nabumetone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Nabumetone.Experimental
Synthetic Conjugated Estrogens, ANabumetone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BNabumetone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusNabumetone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nabumetone.Approved
TalinololNabumetone may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nabumetone.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Nabumetone.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nabumetone.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nabumetone.Approved, Investigational
TemafloxacinNabumetone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Nabumetone.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nabumetone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Nabumetone.Vet Approved
TeriflunomideThe serum concentration of Nabumetone can be decreased when it is combined with Teriflunomide.Approved
TertatololNabumetone may decrease the antihypertensive activities of Tertatolol.Experimental
TheophyllineThe metabolism of Nabumetone can be decreased when combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nabumetone.Approved
TiboloneNabumetone may increase the thrombogenic activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Nabumetone can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNabumetone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Nabumetone.Investigational
TioclomarolNabumetone may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tixocortol.Approved, Withdrawn
TobramycinNabumetone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nabumetone.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nabumetone.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nabumetone.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Nabumetone.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nabumetone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nabumetone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNabumetone may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Nabumetone.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nabumetone.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Nabumetone.Investigational
TrovafloxacinNabumetone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinNabumetone may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nabumetone.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Nabumetone is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinNabumetone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nabumetone.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nabumetone.Approved
VemurafenibThe serum concentration of Nabumetone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Nabumetone.Approved
WarfarinNabumetone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNabumetone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nabumetone.Approved, Investigational
ZeranolNabumetone may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Nabumetone.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Nabumetone.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Nabumetone is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nabumetone.Withdrawn
Zoptarelin doxorubicinNabumetone may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinNabumetone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZucapsaicinThe metabolism of Nabumetone can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food for faster absorption.

References

Synthesis Reference

Brian F. Becnel, Mahmood Sabahi, Kevin J. Theriot, "Production of nabumetone or precursors thereof." U.S. Patent US5907069, issued December, 1985.

US5907069
General References
Not Available
External Links
Human Metabolome Database
HMDB0014604
KEGG Drug
D00425
PubChem Compound
4409
PubChem Substance
46507729
ChemSpider
4256
BindingDB
40128
ChEBI
7443
ChEMBL
CHEMBL1070
Therapeutic Targets Database
DAP000735
PharmGKB
PA450572
HET
NBO
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nabumetone
ATC Codes
M01AX01 — Nabumetone
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
PDB Entries
3taj / 6ci6
FDA label
Download (322 KB)
MSDS
Download (29.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers2
4Unknown StatusTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1

Pharmacoeconomics

Manufacturers
  • Actavis elizabeth llc
  • Copley pharmaceutical inc
  • Dr reddys laboratories ltd
  • Invagen pharmaceuticals inc
  • Matrix laboratories ltd
  • Par pharmaceutical
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Smithkline beecham corp dba glaxosmithkline
Packagers
  • Altura Pharmaceuticals Inc.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Corepharma LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Eon Labs
  • Glenmark Generics Ltd.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • InvaGen Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prescription Dispensing Service Inc.
  • Quality Care
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Sandoz
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
TabletOral500 mg
TabletOral750 mg
Prices
Unit descriptionCostUnit
Relafen 750 mg tablet2.91USD tablet
Relafen 500 mg tablet2.82USD tablet
Nabumetone 750 mg tablet1.56USD tablet
Nabumetone 500 mg tablet1.32USD tablet
Apo-Nabumetone 500 mg Tablet0.39USD tablet
Mylan-Nabumetone 500 mg Tablet0.39USD tablet
Novo-Nabumetone 500 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityPractically insolubleNot Available
logP3.08ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00193 mg/mLALOGPS
logP3.41ALOGPS
logP3.22ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)19.59ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area26.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity68.43 m3·mol-1ChemAxon
Polarizability26.17 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9401
Caco-2 permeable+0.9049
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.5653
P-glycoprotein inhibitor IIInhibitor0.5656
Renal organic cation transporterNon-inhibitor0.7143
CYP450 2C9 substrateNon-substrate0.7664
CYP450 2D6 substrateNon-substrate0.7329
CYP450 3A4 substrateSubstrate0.614
CYP450 1A2 substrateInhibitor0.959
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8591
CYP450 3A4 inhibitorNon-inhibitor0.8235
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6443
Ames testNon AMES toxic0.8942
CarcinogenicityNon-carcinogens0.8745
BiodegradationNot ready biodegradable0.8489
Rat acute toxicity1.7384 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7536
hERG inhibition (predictor II)Non-inhibitor0.8059
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0900000000-6b7de93b51a79132630f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0900000000-af6f3d0d1c5f77f47279
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00fr-2900000000-53d7d6dc809a154d16c2

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Anisoles / Alkyl aryl ethers / Ketones / Organic oxides / Hydrocarbon derivatives
Substituents
Naphthalene / Anisole / Alkyl aryl ether / Ketone / Ether / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Carbonyl group
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
methyl ketone, methoxynaphthalene (CHEBI:7443)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163]
  2. Roy HK, Karolski WJ, Ratashak A: Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer. 2001 May 15;92(4):609-15. [PubMed:11304699]
  3. van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ: A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol. 2002 Jun;53(6):644-7. [PubMed:12047490]
  4. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, Ekbom A: Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004;64(20):2315-43; discussion 2344-5. [PubMed:15456329]
  5. Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995 Aug;109(2):524-30. [PubMed:7615202]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Giuliano F, Ferraz JG, Pereira R, de Nucci G, Warner TD: Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol. 2001 Aug 24;426(1-2):95-103. [PubMed:11525777]
  2. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202. [PubMed:16469680]
  3. Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C, Patrignani P: Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 1995 Sep;58(3):335-41. [PubMed:7554708]
  4. Bensen W, Zizzo A: Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis. Can Fam Physician. 1998 Jan;44:101-2, 105-7. [PubMed:9481468]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Saleh TS, Calixto JB, Medeiros YS: Effects of anti-inflammatory drugs upon nitrate and myeloperoxidase levels in the mouse pleurisy induced by carrageenan. Peptides. 1999;20(8):949-56. [PubMed:10503773]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Turpeinen M, Hofmann U, Klein K, Murdter T, Schwab M, Zanger UM: A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos. 2009 May;37(5):1017-24. doi: 10.1124/dmd.108.025700. Epub 2009 Feb 9. [PubMed:19204080]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:00